NextCure, Inc.
NXTC · United States
Share price · NXTC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NXTC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+17.6%
Nothing announced by NXTC that day or the session before.
- 14 Jul 2026+201.8%
- 1 Jul 2026+21.9%
Nothing announced by NXTC that day or the session before.
- 9 Jun 2026-16.5%
Nothing announced by NXTC that day or the session before.
- 1 Jun 2026-45.5%
- 27 May 2026-13.5%
Nothing announced by NXTC that day or the session before.
- 22 May 2026-23.2%
Nothing announced by NXTC that day or the session before.
- 6 May 2026+15.0%
Nothing announced by NXTC that day or the session before.
- 24 Apr 2026-15.2%
Nothing announced by NXTC that day or the session before.
- 20 Apr 2026+13.3%
Nothing announced by NXTC that day or the session before.
Share of unusual movement by asset
For each asset, the share of NXTC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $4.5M | $8.7M | $6.8M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $7.4M | $15M+ $4.8M short-term inv. | $15M-$9.7M operating cash flow | report ↗ |
| 2026-Q1 | — | $6.8M | $15M+ $15M short-term inv. | $9.8M-$13M operating cash flow | report ↗ |
| 2025-Q3 | — | $6.1M | $7.3M+ $22M short-term inv. | $8.6M-$6.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $24M | $4.9M+ $30M short-term inv. | $27M-$23M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.9M | $22M+ $34M short-term inv. | $11M-$13M operating cash flow | report ↗ |
| 2024-Q3 | — | $8.8M | $28M+ $48M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2024-Q2 | — | $12M | $21M+ $66M short-term inv. | $15M-$9.8M operating cash flow | report ↗ |
| 2024-Q1 | — | $11M | $18M+ $78M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2023-Q3 | — | $11M | $20M+ $99M short-term inv. | $14M-$13M operating cash flow | report ↗ |
| 2023-Q2 | — | $13M | $22M+ $109M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2023-Q1 | — | $12M | $30M+ $116M short-term inv. | $16M-$15M operating cash flow | report ↗ |
| 2022-Q3 | — | $14M | $31M+ $138M short-term inv. | $19M-$15M operating cash flow | report ↗ |
| 2022-Q2 | — | $13M | $28M+ $157M short-term inv. | $18M-$14M operating cash flow | report ↗ |
| 2022-Q1 | — | $15M | $11M+ $191M short-term inv. | $21M-$15M operating cash flow | report ↗ |
| 2021-Q3 | — | $14M | $37M | $18M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $45M | $26M+ $16M short-term inv. | $14M-$50M operating cash flow | report ↗ |
NextCure did not disclose revenue for fiscal year 2025. R&D expense was $44.92M, up 8.3% YoY, and cash, cash equivalents, and marketable securities totaled $41.8M at year-end 2025, down $26.8M from $68.6M at the end of 2024. The company reported a net loss of $55.84M.
Management guided that current financial resources are expected to fund operations and capital expenditures into the first half of 2027 through proof-of-concept for SIM0505. SIM0505 Phase 1 dose escalation data and initiation of a Phase 1 dose optimization study in ovarian cancer are both anticipated in Q2 2026, with an LNCB74 Phase 1 dose escalation trial update planned for the second half of 2026. The company also noted the acquisition of SIM0505 rights and a November 2025 $21.5M private placement.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $41M | $28M+ $41M short-term inv. | $14M-$41M operating cash flow | report ↗ |
| 2023-FY | — | $48M | $13M+ $95M short-term inv. | $16M-$53M operating cash flow | report ↗ |
| 2022-FY | — | $54M | $27M+ $133M short-term inv. | $19M-$54M operating cash flow | report ↗ |
| 2021-FY | — | $50M | $12M+ $207M short-term inv. | $17M-$57M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 19 purchases ($1.9M), 1 sale ($185K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 12,333 | $5.10 | $63K | Form 4 |
| 2026-11-06 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 3,662 | $5.10 | $19K | Form 4 |
| 2026-11-05 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 1,024 | $5.10 | $5K | Form 4 |
| 2026-10-27 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 3,553 | $5.10 | $18K | Form 4 |
| 2026-10-26 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 1,672 | $5.03 | $8K | Form 4 |
| 2026-10-23 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 5,626 | $4.83 | $27K | Form 4 |
| 2026-08-10 | Simcere Zaiming, Inc.; Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Pharmaceutical Group Ltd; Ren Jinsheng; Tang Renhong · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner | Open-market sale | 30,000 | $6.16 | $185K | Form 4 |
| 2026-07-31 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 3,300 | $4.98 | $16K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 2.2M shares ($22.8M, 47.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Squadron Capital Management LLC | 265,000 | $2.8M |
| 2 | Affinity Asset Advisors, LLC | 241,826 | $2.6M |
| 3 | Ikarian Capital, LLC | 238,303 | $2.5M |
| 4 | Sofinnova Investments, Inc. | 222,654 | $2.4M |
| 5 | SILVERARC CAPITAL MANAGEMENT, LLC | 176,057 | $1.9M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 160,473 | $1.7M |
| 7 | Pfizer Inc | 153,354 | $1.5M |
| 8 | Opaleye Management Inc. | 141,181 | $1.5M |
| 9 | AWM Investment Company, Inc. | 117,371 | $1.2M |
| 10 | Exome Asset Management LLC | 115,500 | $1.2M |
| 11 | BOOTHBAY FUND MANAGEMENT, LLC | 69,617 | $744K |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 60,534 | $647K |
| 13 | Verdad Advisers, LP | 42,955 | $459K |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 31,092 | $327K |
| 15 | BlackRock, Inc. | 27,793 | $297K |